Alex C. Sapir is the current CEO and President of Fulcrum Therapeutics, Inc., having stepped into the role on July 1, 2023. Previously, he led ReViral Ltd., a biopharmaceutical firm that specialized in antiviral treatments until its acquisition by Pfizer...

Alex C. Sapir is the current CEO and President of Fulcrum Therapeutics, Inc., having stepped into the role on July 1, 2023. Previously, he led ReViral Ltd., a biopharmaceutical firm that specialized in antiviral treatments until its acquisition by Pfizer in 2022. With a Bachelor's degree in Economics from Franklin and Marshall College and an MBA from Harvard Business School, Sapir combines practical business training with experience in the biotechnology sector. His career includes serving as CEO of Dova Pharmaceuticals, where he focused on treatments for rare diseases and worked as Executive Vice President at United Therapeutics. Notably, he has a significant stake in Fulcrum’s growth—recent trading showed a dramatic increase in his stock holdings, with transactions that reached up to $22.39 million in one month alone. His compensation for 2023 was $990,596, which reflects a mix of salary and performance bonuses. What’s interesting is that despite entering the role mid-year, he quickly earned a bonus for his work and ongoing efforts to guide the company towards its business goals.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Fulcrum Therapeutics, Inc. CEOs

F

Alex C. Sapir

CEO of Fulcrum Therapeutics, Inc.

Education

B.A. in Economics from Franklin and Marshall College, M.B.A. from Harvard Business School.

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

January 1, 1967 - 58 years ago

CEO of Fulcrum Therapeutics, Inc. for

1 year 10 months (Jul 2023 - Present)

Previous Experience

CEO of ReViral Ltd.; CEO of Dova Pharmaceuticals Inc.; Executive Vice President for Marketing and Sales at United Therapeutics Corporation.

Rivals

Competitors/colleagues of Alex C. Sapir

Holdings

See how much did Alex C. Sapir make over time.

Since becoming CEO of Fulcrum Therapeutics, Alex C. Sapir has made notable moves in the stock market, displaying confidence in his company’s future. His insider trading activity included significant investments in Fulcrum, peaking in July 2024 with a hefty $19.56...

Since becoming CEO of Fulcrum Therapeutics, Alex C. Sapir has made notable moves in the stock market, displaying confidence in his company’s future. His insider trading activity included significant investments in Fulcrum, peaking in July 2024 with a hefty $19.56 million purchase. Earlier transactions in early 2024 showed consistent buying activity, totaling around $1.81 million during the months of March to June. The most remarkable part is his initial stakes—he entered at a strategic time, indicating his commitment and belief in Fulcrum's potential for growth. With his recent trades and the current standing of his assets, Sapir’s wealth tied to Fulcrum stocks shows a powerful alignment between personal investment and company success.

Insider Trading

See recent insider trades of Alex C. Sapir.

FULC

$492.03K

FULC at $11.35/share

Mar 4, 2024

Purchase

Compensation History

See how much did Alex C. Sapir make over time.

In 2023, Alex C. Sapir earned a total compensation of $990,596 as the CEO of Fulcrum Therapeutics. This includes a base salary of $369,419 and a performance bonus of $150,000, awarded based on specific business goals. Notably, his compensation package aligns with Fulcrum's overall strategy of rewarding executives for meeting operational objectives. Despite not receiving vested stock in his first year, Sapir was granted stock options reflecting his expected contributions to Fulcrum’s growth over time. His employment terms came with performance metrics designed to drive the company towards yearly targets, ensuring his financial incentives are closely tied to the company's success.

Year

2023

Total Compensation

$591.84K

Salary

$369.42K

Board Justification

The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies, focusing on motivating executives to achieve annual goals based on strategic, financial, and operational performance objectives.

Bonus

$150.00K

Board Justification

The bonus is based on performance metrics and was awarded at 85% of the target for 2023, reflecting Mr. Sapir's pro-rated participation since his employment began in July 2023.

Other

$72.42K

Board Justification

Other compensation includes a housing and travel allowance and a tax gross-up related to the taxable housing and travel allowance.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

The performance metrics for determining the compensation included development goals related to advancing product candidates and operational management.

Other Fulcrum Therapeutics, Inc. CEOs

Here are other CEOs of Fulcrum Therapeutics, Inc.

Robert J. Gould

Ex-CEO of Fulcrum Therapeutics, Inc.

January 2023 - July 2023